Image: LiveU Website

Technion graduates are bringing pictures of the 2012 London Olympics live to your homes. Going live with the 2012 Olympic games, the innovative Israel-born company LiveU introduced an innovative technology that allows a small device to use conventional mobile network signals to broadcast live events, as they happen.


The Technion brain-powered start-up already has a powerful global track record: it delivered live broadcasts of events such as the Royal Wedding of Prince William to Catherine Middleton; the 2011 Oscars and the Grammy Awards 2011; and the 2012 Super Bowl.

London 2012 is also hosting another new Israeli technology: Mobli – according to the Embassy of Israel in London. Mobli – a real-time visual media platform – is being employed by Serena Williams to update her followers on the action in London. Williams is an investor in the company, which is also populated by Technion graduates and was founded by Israeli entrepreneur Moshe Hogeg.
Mobli is the perfect platform for me for sharing my experiences, both the great and the not so great, during the Olympic Games,” said Williams. “I hope that my fans will connect to the channel, to participate and share with me in this unique experience.” 



FDA CLEARS FIRST ROBOTIC-ASSISTED SYSTEM FOR CORONARY ARTERY DISEASE STENT PROCEDURES

Photos: Corindus.



Corindus Vascular Robotics wins 510(k) clearance for CorPath® 200 System; Robotic-assisted percutaneous coronary interventions (PCI) enhances control and protects physicians from radiation


NATICK, Mass. –July 25, 2012 – Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced FDA 510(k) clearance has been granted for the CorPath 200 System to be used in performing percutaneous coronary interventions (PCI). The technology is now approved in the United States to assist interventional cardiologists in performing PCI, a procedure to restore blood flow to blocked arteries in patients with coronary artery disease (CAD).


Corindus was founded in 2000 by Prof. Rafael Beyar, the general director of Rambam Medical Center in Haifa. Its first CEO was Technion graduate Tal Wenderow, who had managed it since it was based at the Technion incubator. The company now operates in Massachusetts and is mainly run by a US team.


Corindus’s product enables doctors to carry out catheterization by full remote using a computer to control the robot’s arms. In this way, the doctor is not exposed to radiation caused by the need for X-ray imaging of the patient to see the location of the implant in the body. In addition, the surgeon is not bending over the patient, but comfortably sitting at a station. The chances of a catheterization doctor getting cancer are much higher than other doctors. Bending over a patient while keeping total concentration, while wearing a lead vest against radiation, causes severe back problems.


“We are pleased to have received clearance from the FDA for the world’s first system designed for roboticassisted PCI procedures,” said David M. Handler, President and CEO of Corindus Vascular Robotics. “This is an important milestone for interventional cardiology as we take the next step in transforming the way these procedures are performed in the future. The CorPath System offers hospitals the opportunity to bring robotic assisted technology benefits to their coronary patients and their physicians.”

“The FDA clearance of the CorPath System will truly change the way I am able to practice. As interventional cardiologists, we perform our procedures using X-ray guidance and are cognizant that throughout our careers, we will be exposed to a high amount of radiation. In the past, we have relied on heavy lead aprons to protect us from radiation, but the physical stress of wearing these aprons can lead to back pain, fatigue and orthopedic injuries,” said Joseph P. Carrozza, Jr. M.D., Chief of Cardiovascular Medicine at St. Elizabeth’s Medical Center in Boston. “Robot-assisted PCI procedures allow us to provide our patients with the highest quality of care working in an ergonomic position with robotic-assisted stent and balloon placements to restore blood flow.”

Recent data published in Catheterization and Cardiovascular Intervention journal demonstrated an interventional cardiologist’s daily exposure to radiation and the physical stresses inherent in the cath lab can lead to occupational health risks, including orthopedic problems, cataracts, and cancer. The CorPath PRECISE Trial—a prospective, single-arm, multi-center, study, which served as the basis for the submission of a premarket clearance (510(k)) application to the FDA— demonstrated that robotically-assisted PCI is safe and feasible for patients. PCI was successfully completed without having to convert to manual PCI in 98.8 percent of patients and without device-related complications. The overall procedure success rate was 97.6 percent.


Additionally, the trial found that robotic-assisted PCI can make the procedure safer for the interventional cardiologist by reducing the radiation exposure by 95 percent when performing the procedure with the CorPath 200 System.

“Gaining significant experience with the CorPath 200 System, I was impressed with its performance and the precise control of the interventional devices, including manipulating the guidewire and stent and being able to move the devices precisely in increments as small as one millimeter,” said Giora Weisz, M.D., Director of Clinical Research at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Associate Professor of Medicine at Columbia University College of Physicians and Surgeons, New York.

“Working with this robotic technology is very intuitive and the PRECISE trial demonstrated its applicability in today’s cath lab environment. I strongly believe robotic-assisted PCI will enhance the way we are conducting PCI, and we are looking forward to adapting it in our everyday practice.”

The CorPath 200 System is the first and only robotic-assisted procedure to allow for controlled placement of coronary guidewires and stent/balloon catheters from an optimized interventional cockpit. The lead-lined cockpit protects the interventional cardiologist from harmful radiation exposure and the seated position in front of monitors may provide enhanced view of the angiography screen while reducing fatigue and minimizing head, neck and back strain.

“There has been a tremendous amount of interest in the CorPath 200 System, and we are excited to bring to market a solution that has the potential to transform the standard of care for PCI procedures,” said Handler. “Corindus is ready to help our customers successfully implement the complete CorPath-assisted procedure program into their institutions.”

About Corindus Vascular Robotics

Corindus Vascular Robotics (http://www.corindus.com) is the global technology leader in robotic-assisted percutaneous coronary interventions. The Company’s FDA cleared CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. The CorPath open-platform technology and intellectual property will enable Corindus to address other segments of the vascular market, including peripheral, neuro and structural heart applications.

Corindus Media Contacts:
Corindus Vascular Robotics Schwartz MSL
Tal Wenderow Lloyd Benson/Krystin Hayward
(508) 653-3335 ext. 205 (781) 684-0770
tal.wenderow@corindus.com corindus@schwartzmsl.com
Corindus was formed out of Technion Patented innovation. Search for new patents and innovation from Technion, Israel at T3-Technion Technology Transfer.
Prof. Dan Shechtman is a research professor in the Faculty of Materials Engineering at the Technion – Israel Institute of Technology. In 2011, he was awarded the Nobel Prize in Chemistry for his discovery of quasicrystals. But not a lot of people know that he is also a talented jewelry craftsman.
1972, Dayton, Ohio. It all began innocently enough. Zippi, Dan’s wife, was busy in the evenings studying for a Master’s Degree in Sociology, and Dan Shechtman, a postdoctoral fellow, found himself studying stone polishing in the arts center during his free time.   Before long, five pairs of polished stones accumulated. Each pair, a different color. What would he do with them? He found himself attending a silver jewelry making course, from that moment onwards, sensitively and delicately, Dan has been creating and designing jewelry. Jewelry for his wife: only for his wife.
An exhibition of handcrafted jewelry created by Nobel Laureate Dan Shechtman was displayed on campus. The exhibition showcased 15 unique pieces ranging from earrings, necklaces and bracelets with a single item — an Aztec-inspired silver belt buckle— which Distinguished Prof. Shechtman made for himself.
The exhibition, curated by Anat Har-Gil, took place June 10 to June 14, 2012, on campus.
Mazor Robotics Renaissance surgical system
Image: Mazor Website.



FDA approves Mazor robot for brain surgery

“As neurosurgeons focus on both the spine and brain, brain surgeries represent a large market opportunity that is closely aligned with our current focus.”

Mazor Robotics Ltd. has announced that it has obtained US Food and Drug Administration (FDA) approval for its Renaissance surgical guidance system for brain surgery, in addition to spinal procedures. The company will include the brain surgical capability in the same device currently sold for spinal procedures
.
Mazor CEO Ori Hadomi has said in the past that Mazor is a company operating in the spinal procedures field, and that it expected to remain so. The expansion to the brain surgical field is an important addition, but not a core business. Mazor has previously said that the addition of new capabilities to the Renaissance surgical guidance system could allow the company to raise the system’s price, which is currently $750,000 per unit for the spinal surgery version.


Mazor had NIS 9.2 million in sales for the first quarter of 2012. Since April, the company has announced the sale of five additional systems in the US. The company also operates in other countries, where prices for its systems are a bit less than in the US, but the number of sales is about the same. The company obtained marketing approval in South Korea in June.


Mazor is now waiting for EU CE Mark approval for the marketing of the Renaissance system for brain surgery in Europe, where it is currently limited to use for spinal surgical procedures.


Mazor Surgical Technologies has pioneered the development of miniature Semi robotic bone mounted positioning systems SmartAssist platform for a wide range of orthopedic procedures. Mazor is a leading provider of the SpineAssist, a highly accurate, minimally invasive, easy-to-use, miniature surgical assistance system for a wide range of spine procedures. The company was founded by Prof. Moshe Shoham of the Technion Faculty of Mechanical Engineering in order to put his patented robotic innovations into practice.



The Renaissance technology, a surgical guidance system originally designed for use in spine surgeries, is applicable in brain procedures for many applications including biopsies, shunt placements and neurostimulation electrode placement for deep brain stimulation (DBS). Along with the system’s precision, simplicity, and safety profile, the Renaissance System will also provide a frameless treatment solution for brain procedures. Renaissance has already been successfully employed in several clinical brain surgical procedures in Europe. 34 hospitals globally are currently using Renaissance for the different types of spine surgery.
“While our core is spine surgery, we are thrilled that our technology can be expanded to improve other surgical procedures,” stated Ori Hadomi, chief executive officer. “As neurosurgeons focus on both the spine and brain, brain surgeries represent a large market opportunity that is closely aligned with our current focus. Achieving U.S. regulatory clearance provides us with the opportunity to assist neurosurgeons in improving brain surgery processes and the ensuing clinical outcomes.”

This causes serious health problems to the infants and the mothers must provide them with a zinc-containing supplement; the researchers have developed a simple genetic test to identify mutations in the gene, which will allow pre-pregnancy screening

Technion researchers headed by Prof. Yehuda G. Assaraf and the doctoral student Inbal Lasry of the Faculty of Biology, in collaboration with researchers from the Sheba Medical Center, have identified and characterized a mutation in breastfeeding mothers which leads to zinc-deficient milk and could in turn cause serious health problems in exclusively breastfed Infants. These findings were published in the scientific Journal of Biological Chemistry and have garnered substantial interest, as breast milk is perceived as always being healthy for the infant.

“Zinc is a mineral which plays an essential role in growth and development processes, including the development of cognitive and motor functions of the brain as well as the proper function of the immune system and the skin. Thus, zinc is a highly essential mineral particularly for infants, as they undergo accelerated growth and development processes”, explains Prof. Assaraf, head of the Fred Wyszkowski Cancer Research Laboratory in the Faculty of Biology at the Technion. “A large number of proteins in our body relies on zinc for their normal function”, adds Prof. Assaraf.  Zinc deficiency could lead to rashes and dermatitis that have the appearance of severe burns; it could alos lead to diarrhea, hair loss, loss of appetite, impaired function of the immune system and impaired function of the nervous system”. Thus, for example, zinc deficiency could impede our ability to defend ourselves, through the immune system and the inflammation process, against foreign pathogens such as bacteria, viruses, and parasites.

The research was conducted in collaboration with a team from the Edmond and Lily Safra Children’s Hospital in the Sheba Medical Center, headed by Dr. Yair Anikster, Director of the Pediatric Metabolic Diseases Unit. The research began with the referral, by Soroka University Medical Center and Bikur-Holim Hospital, of two infants from two different Israeli families who suffered, among others, from an especially severe rash which has the appearance of a severe burn. Blood tests and breast milk analysis led to the hypothesis that the illness is due to zinc deficiency, and this in turn led the researchers to examine the sequence of the ZnT-2 gene. The importance of the ZnT-2 transporter is critical during the breastfeeding period because it acts as a transporter which delivers zinc from the mother’s blood to the breast milk on which the infant feeds. The researchers identified in the mothers, a specific mutation in the ZnT-2 gene in a highly evolutionarily conserved region, that appeared essential for the preservation of the proper structure and function of this zinc transporter protein. “We have discovered that the mutation in the ZnT-2 zinc transporter disrupts its activity, and this consequently prevents the transport of zinc to the breast milk. As a result, an infant who is exclusively breastfed and who does not receive any food supplement does not receive the appropriate zinc levels, which in turn leads to disease”, explains Prof. Assaraf. This part of the research was conducted in collaboration with Prof. Shannon L. Kelleher of Pennsylvania State University, USA.

“Every gene has two genetic components known as alleles – one originates from the father and the other from the mother. In the present disease – one of the two alleles was defective. Supposedly, the second, healthy allele, being entirely normal, should have protected the infant from this defect”, explains Prof. Assaraf. The Technion researchers have found an answer to this scientific-medical dilemma: the current research made the discovery that the ZnT-2 zinc transporter operates as a couple known as a dimer, namely: two identical ZnT-2 proteins couple to create the mature, active zinc transporter which transfers zinc from the mother’s blood to the breast milk. Therefore, if one of these proteins is impaired – the zinc transporter becomes inactive. That is, even a single mutation, either in the paternal allele or in the maternal one, is sufficient to shut the zinc transporter down, a phenomenon known in the scientific language as a dominant negative effect.

This discovery paves the way for pre-pregnancy genetic screening in women, toward providing them with genetic counseling to clarify to those of them who harbors the defective gene that while they are breastfeeding, they will have to provide their baby with a zinc-containing food supplement, in order to avoid health problems to the infant. Among others, the researchers are currently examining the prevalence of the mutations in the ZnT-2 gene.

Technion Researchers Construct a Polymeric Scaffold Array with Pancreatic Islets Surrounded by a Vascular Network. This heralds the potential for the fabrication of transplantable “islets”.



Technion researchers have succeeded in constructing a three-dimensional polymeric scaffold array with pancreatic islets surrounded by a vascular network, reports the scientific journal PLoS ONE.
“We have shown that the three-dimensional environment and the engineered blood vessels support the islets – and this support is important for the survival of the islets and for their insulin secretion activity”, says Prof. Shulamit Levenberg of the Department of Biomedical Engineering. “We have shown that these laboratory-made polymeric scaffolds can be transplanted subcutaneously and can heal a diabetic mouse. The ability to increase the islets’ vasculature and to support their post-transplant survival could allow the transplant of four times less islets than is customary in transplants in mice, while still achieving decreased blood sugar levels and diabetes relief”. 
The mechanism which causes the failure of pancreatic islet transplants is as yet not entirely clear, but the prevailing opinion is that it has to do with ischemic damage – and a delay in the creation of new blood vessels.
The Technion researchers hypothesize that blood vessels also have an active role in inter-cellular communication that supports the survival and function of pancreatic islets. To test this hypothesis, the researchers developed a three-dimensional network of endothelial blood vessels in engineered pancreatic tissues produced from islets, fibroblasts and endothelial cells. This triple array, which was seeded on highly porous polymeric scaffolds, mimics the natural anatomical context of pancreatic vasculature.
“We have shown that the increase in islet survival is correlated with creation of surrounding endothelial tubes”, says Prof. Levenberg. “Adding fibroblasts to pancreatic islet and endothelial cell cultures encouraged the creation of the vascular network, which supported islet survival as well as insulin secretion. Significant differences were seen in many variables – gene expressions, profiles of the growth factors of endothelial cells, ECM, morphogens and screening markers – between two-dimensional culture systems and three-dimensional culture systems that allow an endothelial network, and such differences were even greater after fibroblasts were added that support the creation of the engineered blood vessels.”
Transplanting the vascularized engineered islet tissue has improved the survival and acceptance of such islets in diabetic mice, and has even improved their function in decreasing blood glucose. The Technion researchers hope that these findings herald potential strategies for the fabrication of transplantable islets with improved survivability.
The work was done by research student Keren Francis in Prof. Levenberg’s laboratory and in cooperation with Yuval Dor from the Hebrew university, under a joint research grant provided by Juvenile Diabetes Research Foundation International.
The laboratory is now researching the effect of the vascular network and the three-dimensional growth on human islets, under joint finance of the Juvenile Diabetes Research Foundation International and the Israel Science Foundation.  


Published Scientific Paper.

PATENT DETAILS3D vascularized pancreatic islets – for islets transplantation
Ref. CTT-0895
The present invention provides a unique 3D pancreatic-like model for co-culture of isolated pancreatic islets with endothelial cells on a PLLA/PLGA biodegradable polymeric scaffold.
Insulin-dependent diabetes mellitus (IDDM) is a chronic inflammatory disease in which there is autoimmune-mediated organ-specific destruction of insulin-producing beta cells in the pancreatic islets of Langerhans, resulting in glucose homeostasis abnormalities and metabolic complications that are debilitating and life-threatening. Islet transplantation is a potentially curative treatment since replacement of these cells could prevent mortality, however thus far islet cell transplantation has had poor success due mainly to the fact that the tissue grafts must establish new vasculature from the host to survive. Native islets in the pancreas have a rich microvasculature that provides efficient oxygen and nutrient delivery and ensures rapid dispersal of pancreatic hormones to the circulation, and therefore after implantation, the survival and function of islet grafts depends on reestablishment of new blood vessels. During the time required for revascularization, there is a much-increased susceptibility to loss from ischemic injury, so that rapid and adequate islet revascularization is crucial for the survival and function of transplanted islets. In both experimental and clinical islet transplantations, islets are cultured for several days between isolation and transplantation.
The present invention provides an advanced tissue-engineering technique for development of 3D co-culture systems that reconstruct vascularization of pancreatic tissue ex-vivo. In this novel engineered 3D pancreatic model, isolated pancreatic islets can be co-cultured with endothelial cells using PLLA/PLGA biodegradable polymeric scaffolds. The endothelial cells organize into 3D tubes throughout the engineered construct and form vascular network-like structures resembling in-vivo vasculature. This presence of endothelial cells forming 3D vessel-like structures was found critical for islet survival. This model can provide an important tool for therapeutic transplantation of islets, greatly increasing the success of the procedure by increasing islet survival and reducing the number of organ donors needed per transplant and the number of repeated transplants, making this procedure more available, biologically and economically. This model also provides new exciting tools for studying central problems in molecular and cell biology of the pancreas.
In the U.S, an estimated 20.8 million people (7% of the population) have diabetes mellitus. In the next five years, around US$2.5 billion will be spent worldwide on diabetes mellitus research. 

 

This heralds the potential for the fabrication of transplantable “islets”

The scientific journal PLoS ONE reports that Technion researchers have succeeded in constructing a three-dimensional polymeric scaffold array with pancreatic islets surrounded by a vascular network.

“We have shown that the three-dimensional environment and the engineered blood vessels support the islets – and this support is important for the survival of the islets and for their insulin secretion activity”, says Prof. Shulamit Levenberg of the Department of Biomedical Engineering. “We have shown that these laboratory-made polymeric scaffolds can be transplanted subcutaneously and can heal a diabetic mouse. The ability to increase the islets’ vasculature and to support their post-transplant survival could allow the transplant of four times less islets than is customary in transplants in mice, while still achieving decreased blood sugar levels and diabetes relief”.

The mechanism which causes the failure of pancreatic islet transplants is as yet not entirely clear, but the prevailing opinion is that it has to do with ischemic damage – and a delay in the creation of new blood vessels. The Technion researchers hypothesize that blood vessels also have an active role in intercellular communication that supports the survival and function of pancreatic islets. To test this hypothesis, the researchers developed a three-dimensional network of endothelial blood vessels in engineered pancreatic tissues produced from islets, fibroblasts and endothelial cells. This triple array, which was seeded on highly porous polymeric scaffolds, mimics the natural anatomical context of pancreatic vasculature. “We have shown that the increase in islet survival is correlated with creation of surrounding endothelial tubes”, says Prof. Levenberg. “Adding fibroblasts to pancreatic islet and endothelial cell cultures encouraged the creation of the vascular network, which supported islet survival as well as insulin secretion. Significant differences were seen in many variables – gene expressions, profiles of the growth factors of endothelial cells, ECM, morphogens and screening markers – between two-dimensional culture systems and three-dimensional culture systems that allow an endothelial network, and such differences were even greater after fibroblasts were added that support the creation of the engineered blood vessels.”

Transplanting the vascularized engineered islet tissue has improved the survival and acceptant of such islets in diabetic mice, and has even improved their function in decreasing blood glucose. The Technion researchers hope that these findings herald potential strategies for the fabrication of transplantable islets with improved survivability.

The work was done by research student Keren Francis in Prof. Levenberg’s laboratory and in cooperation with Yuval Dor from the Hebrew university, under a joint research grant provided by Juvenile Diabetes Research Foundation International. The laboratory is currently conducting a continuing research of the effect of the vascular network and the three-dimensional growth on human islets, under joint finance of the Juvenile Diabetes Research Foundation International and the Israel Science Foundation.

atlas.jpg
A view of the center of the ATLAS

Technion researchers are playing important roles at the LHC project in CERN – the world’s most powerful particle accelerator.  Recently, news reports say the greatest scientific experiment in history has had amazing results and that the Higgs Boson – alias the “God particle” – has been discovered.

During the sixties and seventies, a model was developed that explains phenomena observed in the world of particles that comprise the entire universe. The model, which is called the “Standard Model”, explains brilliantly and accurately all experimental results and observations. But this model has originally had a problem: it could not be used to explain particles that have a mass. It is simply that mathematically, the equations did not hold if the mass of these particles was added to them. In the mid-sixties, several physicists, among them Peter Higgs, suggested what is currently known as the “Higgs mechanism”, through which mass can be added to the Standard Model. But adding this mechanism meant that a new particle had to exist – the Higgs Boson. We have been searching for it ever since. Last night, the world was told of its discovery.

This is, without a doubt, a technological achievement, but the real achievement is not in the technological realm, but rather in the news that the model we have been following is likely the correct one. We have, in fact, completed our first puzzle. We can now safely proceed in search of the next puzzle, namely the “new physics” or “physics beyond the Standard Model”, where we investigate phenomena that are not described by the Standard Model. Each such discovery, if made, will completely change our perception of the universe around us.

The Technion group has made a major contribution to the discovery, in that the construction and examination of the muon detectors, which are a critical part of the experiment’s ability to measure the events, were done in Israel.  The muon detection software was developed by Prof. Tarem, and Prof. Rozen is responsible for the tremendous grid computing system. Students guided by Prof. Tarem developed the detector control system, and several students and researchers are now working under her guidance on one of the Higgs decay channels, as presented in the press conference last night.

About three years ago, only a moment before the huge tunnel in which the accelerator was built was sealed, Avi Blizovsky visited the place and we now bring his impressions once again.

We visited “ATLAS” – one of the main detectors in the LHC project in CERN. In a modest office in building number 40 – one of the main buildings on the CERN campus – seats Prof. Shlomit Tarem, of the High Energy Group in the Technion’s Department of Physics. Prof. Tarem is participating in the project together with her colleague in the group, Prof. Yoram Rozen, and their graduate students. The office houses also post-doctoral fellow Sofia Vallecorsa (originally of Rome) and doctoral student Sagi Ben-Ami. Among the Israeli group members are also researchers from the Weizmann Institute and Tel Aviv University. With them works Arwa Bannoura, a student from Birzeit who lives in Bethlehem,  and who is  currently in CERN for the summer semester.

The Israeli group is headed by Giora Mikenberg of the Weizmann Institute, who has held in the past formal positions in CERN. According to Mikenberg, the credit for Israel joining the project is due, first and foremost, to the late Prof. Paul Singer of the Technion’s Department of Physics, who served as Chairman of the Israel Science Foundation.

During its construction, Israeli engineers collaborated with engineers of the Pakistan Atomic Energy Commission, and Israeli equipment allows fast and accurate optical communications between the facilities and the enormous server cluster. Many Israeli companies participated in building “ATLAS”, the huge facility that comprises 2,700 detectors on eight “wheels” 20 meters in diameter. Once the tunnel was sealed in August it could no longer be entered, which emphasizes the importance of the examinations conducted toward this move, to avoid technicians having to enter the tunnel in order to make repairs once the experiment begins.

The different elements of the CERN project were indeed examined prior to the start of the experiment, but the operation of the project as a whole could not be tested at the time. As was announced, the project was shut down for two months shortly after it began, because of a helium leak, but Prof. Tarem cautions against any concern. “This experiment will last for at least a decade, so two months are not too significant a period. Besides, malfunctions cannot be avoided in such a big, complicated experiment.”

Today, Profs. Tarem and Rozen and thousands of their colleagues worldwide can smile with pride and satisfaction.  They were part of the discovery of the “God particle”.

cern.jpg
A graphic diagram of the particle accelerator in Geneva
rozen-team.jpg
From right to left: Eli Hadash, Shikma Bressler, Silvia Behar, David Cohen, Yoram Gernitzky, Alon Hershenhorn and Yaniv Katan. In the second row: Sofia Vallecorsa, Dikla Oren, and Enrique Kachomovitz. Prof. Rozen (horizontal).
You might also like:



Intel buys heart beat biometrics company IDesia Biometrics, which provides technology through which heart beats can be used to recognize users on PCs and mobile devices

Idesia Biometrics  provides technology through which heart beats can be used to recognise users on PCs and mobile devices. The technology can also be used to provide health information.


With over 500 patents to his name, Technion graduate and co-founder of Idesia Biometrics Yossi Gross is one of Israel’s most powerful pioneers at the vanguard of biotech innovation. Launching his technological career within the Lavi program of Israel Aircraft Industries (IAI), Gross went on to initiate 27 medical device companies. Intel’s recent acquisition could be energized by the search for more secure forms of identifying users, and/or even by its new ventures into mobile applications for health care. Idesia has 14 employees of which 10 are in Israel.


Co-founder and inventor Technion graduate of Electrical Engineering (1987) Dr. Danny Lange is also an ongoing source of biotech innovation.  “As an entrepreneur, the most important thing is that the technology will be brought to market, and it looks like Intel is the company that can ensure that,” Lange told Globes , which first reported the story.

Dr. Danny Lange
Dr. Danny Lange,
Technion graduate in Electrical Engineering.
Lange is experienced in running both fledgling and well-established technology businesses. Prior to IDesia, he co-founded and held executive positions of two medical device companies in the field of patient monitoring (Algodyne Ltd. and Earlysense Ltd.), invented their core technologies and authored more than a dozen patents covering his inventions. Earlier still, Dr. Lange served as senior R&D engineer at Hewlett-Packard Research Laboratories, and as a Research Associate and Lecturer at the Technion – Israel Institute of Technology. Dr. Lange holds a B.Sc., M.Sc. and Ph.D., all in Electrical Engineering from the Technion – Israel Institute of Technology.



Intel has not yet commented on how much it paid for Idesia or how it will use the biometric technology. Fingerprint readers and face recognition have been used for some time to recognize users, but there are concerns that those technologies can be easily tricked. Monitoring heart beats could provide Intel a more advanced and secure way to recognize users.


Technion graduates at Intel’s R&D center in Israel developed the architecture behind the popular Core and Core 2 microprocessors, and the country’s operations are headed by Technion graduate Mooly Eden, who previously managed the PC client group at Intel.

Intel has a big interest in the health care industry and is in a joint venture with General Electric to provide in-home heath care products. The joint venture, called Care Innovations, provides products like tablets targeted at the health care industry. Intel is also conducting research on health care for senior citizens.


Technion Alumn Yossi Gross 
Gross received an MSc degree in 1976 in aeronautical engineering. 

Technion graduate Yossi Gross (born February 5, 1947) is an Israeli medical device innovator and entrepreneur. He is a founding partner of Rainbow Medical, an operational investment company, established to launch companies based on the technological ideas and inventions of Gross. Gross first started his professional career as a project manager of the Lavi (IAI Lavi ) program for the Israel Air Force. 

Since the 1990, Gross initiated 27 medical device companies based on his various inventions in electronics, signal processing, nanotechnology, drug delivery and neurostimulation. Gross’s companies have developed or are currently developing treatments for diabetes, gastroenterology, stroke, ophthalmology, asthma, congestive heart failure, and urology. In total, Gross has 567 filed patents.


See also: The Creative Mind of Yossi Gross [PDF]

Also on the IDeasia Biometrics Team:

Dikla Horesh

Technion graduate Dikla Horesh: 
Over 5 years experience as Biomedical engineer in IDesia Biometrics and Healthcare.
ECG signal processing as part of the Algorithm team for 3 years.
Managed the consumer Healthcare department in IDesia for 2 years.

You might also like:

Technion graduate Mooly Eden named as among CNN’s top 10 Technological visionaries in June 2012.

Shmuel (Mooly) Eden is vice president and general manager of the PC Client Group (PCCG). In this capacity, he is responsible for the platform planning, architecture, enabling and marketing of Intel’s PC solutions for the desktop and mobile computing segments.
Eden joined Intel in 1982. He held numerous technical and management positions in microprocessor design for several Intel microprocessors, including the Intel® Pentium® processor with MMX™ technology. From 1999 – 2003 Eden was director and general manager of the Israel Development Center. He was responsible for the development of the mobile microprocessors and chipsets, including Intel® Centrino® Processor Technology and the Intel® Pentium® M processor, formerly codenamed Banias.
In 2004 he served as vice president and director of marketing for the Mobile Platforms Group, responsible for driving growth in the notebook computing segment. In 2005 he was promoted to vice president and general manager of the Mobile Platforms Group, where he was responsible for ramping the notebook and later on the netbook categories. In 2009 he was promoted to the current position as the vice president and general manager of the PC client group.
Prior to joining Intel in 1982, Eden was an engineer for Tadiran Communication, Ltd. Eden received a bachelor’s degree in electrical engineering from the Technion Institute of Technology in Israel in 1973 and a senior business management degree from Jerusalem University. He taught as an adjunct senior lecturer at the MBA program of the Technion Institute of Technology from 1999 – 2002.